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Abstract
Objective
To evaluate the association of perihemorrhagic edema (PHE) evolution and peak edema extent
with day 90 functional outcome in patients with intracerebral hemorrhage (ICH) and identify
pathophysiologic factors inﬂuencing edema evolution.
Methods
This retrospective cohort study included patients with spontaneous supratentorial ICH be-
tween January 2006 and January 2014. ICH and PHE volumes were studied using a validated
semiautomatic volumetric algorithm. Multivariable logistic regression and propensity score
matching (PSM) accounting for age, ICH volume, and location were used for assessing
measures associated with functional outcome and PHE evolution. Clinical outcome on day 90
was assessed using the modiﬁed Rankin Scale (0–3 = favorable, 4–6 = poor).
Results
A total of 292 patients were included. Median age was 70 years (interquartile range [IQR]
62–78), median ICH volume on admission 17.7 mL (IQR 7.9–40.2). Besides established
factors for functional outcome, i.e., ICH volume and location, age, intraventricular hemorrhage,
and NIH Stroke Scale score on admission, multivariable logistic regression revealed peak PHE
volume (odds ratio [OR] 0.984 [95% conﬁdence interval (CI) 0.973–0.994]) as an in-
dependent predictor of day 90 outcome. Peak PHE volume was independently associated with
initial PHE increase up to day 3 (OR 1.060 [95% CI 1.018–1.103]) and neutrophil
to lymphocyte ratio on day 6 (OR 1.236 [95% CI 1.034–1.477; PSM cohort, n = 124]). Initial
PHE increase (PSM cohort, n = 224) was independently related to hematoma expansion
(OR 3.647 [95% CI 1.533–8.679]) and fever burden on days 2–3 (OR 1.456 [95% CI
1.103–1.920]).
Conclusion
Our ﬁndings suggest that peak PHE volume represents an independent predictor of functional
outcome after ICH. Inﬂammatory processes and hematoma expansion seem to be involved in
PHE evolution and may represent important treatment targets.
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In intracerebral hemorrhage (ICH), there are many detri-
mental processes and secondary damage cascades, including
inﬂammation and degradation of heme products, initiated
immediately after ICH onset. They are hypothesized to
contribute to the development of perihemorrhagic edema
(PHE), which is suggested to serve as a radiologic marker for
secondary injury following ICH.1–4 PHE volume may evolve
within a period of 8–12 days after ictus and may exceed the
initial lesion volume by more than 150%,3 possibly causing
clinical deterioration or even herniation.5 Thus, PHE evolu-
tion and notably peak PHE volume may represent important
outcome measures and treatment targets not only in the
(hyper-)acute phase of ICH while established prognostic
outcomemeasures (e.g., initial hematoma volume or age1) are
rather inaccessible to a treatment or show limited treatment
options.1,6–8 Speciﬁcally, several research groups reported on
an association of early PHE evolution up to 24–72 hours after
ICH onset with functional outcome.9–12 However, as PHE
volume may peak 8–12 days after onset, analyzing PHE
evolution merely up to 72 hours after onset may yield limited
results. In the present study, we correlated peak PHE volume
with long-term outcome in ICH patients. Furthermore, we
assessed factors associated with increased PHE evolution.
Methods
Patients
Our study retrospectively included patients with spontaneous
supratentorial ICH who were admitted between January 2006
and January 2014 from our prospectively organized in-
stitutional database. We deﬁned ICH as spontaneous if ex-
clusively related to hypertension or amyloid angiopathy.
Patients with secondary ICH were excluded. Inclusion criteria
were at least 2 consecutive CT scans over a period of at least
72 hours, no withdrawal of care within 24 hours after ad-
mission, an available modiﬁed Rankin Scale score (mRS) on
day 90, and a baseline mRS of <4. Furthermore, we excluded
patients with surgical hematoma evacuation.
Standard protocol approvals, registrations,
and patient consents
The study was approved by our institutional ethics committee.
Clinical data
We obtained age,1 mRS before symptom onset, NIH Stroke
Scale score (NIHSS) on admission,1 and other outcome
predicting measures in ICH such as fever burden (deﬁned as
number of days with peak temperature ≥38°C) up to day 1213
and serum inﬂammatory measures14 including lymphocytes,
neutrophils, and neutrophil to lymphocyte ratio (NLR; neu-
trophil count divided by lymphocyte count) on admission and
days 4 and 6 as a marker for systemic inﬂammation also rel-
evant for cardiovascular outcomes15 and elevated intracranial
pressure (ICP) burden (number of episodes with ICP
>20 mm Hg lasting more than 5 minutes or with patients
presenting with symptoms related to elevated ICP [de-
terioration of consciousness, anisocoria]) up to day 12 from
medical records. We used standardized mailed questionnaires
for the assessment of functional status before symptom onset
and comorbidities if those data were not obtained during
hospital stay. Time between symptom onset and admission
was assessed as an important predictor of hematoma expan-
sion.16 The day of admission was deﬁned as day 1.
Neuroimaging and volumetric assessment of
PHE and ICH
A fourth-generation CT scanner (Somatom 64 or Somatom
AS+, Siemens Healthcare, Erlangen) was used for CT scans.
Each scan consisted of either a multislice spiral CT dataset,
10–12 slices of 4.8 mm thickness for the skull base and 10–12
slices of 7.2 mm thickness for the cerebrum (Somatom 64), or
22–25 slices of 4.8 mm thickness for the entire brain
(Somatom AS+) using the orbitomeatal plane. We used
a validated semiautomatic volumetric algorithm as previously
described17 for assessment of ICH and PHE volume. For
better comparison, we merged diﬀerent time points of CT
scans to time clusters (days 1, 2–3, 4–6, 7–9, 10–12). Initial
PHE growth from baseline to 72 hours9–12,18 (deﬁned as
absolute diﬀerence between PHE volume [mL] on day 2–3
and admission), intraventricular hemorrhage (IVH), and he-
matoma volume on admission19 as well as peak PHE volume
and secondary hematoma enlargement (hematoma expan-
sion) volume were recorded. Peak PHE volume was deﬁned
as the maximum volume measured in any of the available CT
scans. In the context of accuracy of measurements,20,21 a he-
matoma volume increase ≥ 5 mL between 2 CT scans was
deﬁned as hematoma expansion.7
Outcome
We assessed functional outcome on day 90 using the
mRS either by mailed standardized questionnaires or phone
interviews (performed by trained and certiﬁed physicians)
with patients or their next of kin if the questionnaire was not
returned within 4 weeks.22 In cases of insuﬃcient data re-
trieval, we contacted primary care physicians. As primary
outcome variable, mRS was dichotomized as favorable out-
come (mRS 0–3) or poor outcome (mRS 4–6). As secondary
Glossary
CI = conﬁdence interval; ICH = intracerebral hemorrhage; ICP = intracranial pressure; IQR = interquartile range; IVH =
intraventricular hemorrhage; mRS = modiﬁed Rankin Scale; NIHSS = NIH Stroke Scale; NLR = neutrophil to lymphocyte
ratio; PHE = perihemorrhagic edema; PSM = propensity score–matched; OR = odds ratio; ROC = receiver operating
characteristic.
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outcome measures, we analyzed the correlation of clinical
characteristics and inﬂammatory measures with peak PHE
volume and early PHE growth from baseline up to day 3 (72
hours). Patients were dichotomized according tomedian peak
PHE volumes and median early PHE increase volumes.
Statistics
We performed statistical analyses using the IBMSPSS Statistics
21 software package (IBM Corporation, Armonk, NY) and R
2.12.0 (r-project.org). The signiﬁcance level was set at α = 0.05
and statistical tests were 2-sided. Missing data regarding basic
characteristics, neuroimaging, or outcome led to exclusion of
patients.We used the Kolmogorov-Smirnov test to evaluate the
distribution of data. Data were presented as mean ± SD (sta-
tistical test: Student t test), or as median and interquartile range
(IQR, statistical test: Mann-Whitney U test), as appropriate.
We used Pearson χ2 or Fisher exact test to compare frequency
distributions of categorized variables between dichotomized
patient groups: (1) mRS 0–3 and 4–6, (2) patients with peak
PHE volume smaller and larger than the median peak PHE
volume, and (3) patients with an early PHE increase smaller
and larger than the median increase of the included cohort
(median split). For both groups 2 and 3, we performed a sep-
arate additional propensity score matching using the entire
cohort (n = 292) based on logistic regression as estimation
algorithm (nearest neighbor matching, ratio 1:1, caliper = 0.1)
accounting for age, hematoma volume, and hematoma location
(basal ganglia vs lobar) and calculated abovementioned uni-
variate testing as well as additional logistic regression. To
identify measures independently associated with outcome and
peak PHE volume, we calculated stepwise backward inclusion
multivariate logistic regression models including clinically
meaningful measures showing a statistical trend (p < 0.1) in
univariate testing of the entire cohort. As hematoma location
(lobar vs basal ganglia) was demonstrated previously to rep-
resent an important outcome associated factor23 with a sug-
gested interaction with hematoma volume,24 we also included
the interaction term of both factors in our multivariate logistic
regressionmodel. Because not all patients had regular CT scans
up to day 10–12 based on inclusion criteria, we performed an
additional sensitivity analysis including only patients with at
least 4 CT scans up to day 9. To explore associations of PHE
evolution with outcome, we additionally performed receiver
operating characteristic (ROC) curve analyses.
Results
Cohort
A total of 875 patients were screened. We excluded 154
patients who received early withdrawal of care, 53 patients
because of surgery (hematoma evacuation) prior to control
scan, and 140 patients who had only 1 CT scan. A further 38
patients were excluded due to insuﬃcient datasets, 143 due to
infratentorial hemorrhage, and 55 due to a mRS prior to the
current ICH of >3. This led to 292 patients (161 male [55%])
who met inclusion criteria. A total of 121 (41%) patients pre-
sented with lobar hemorrhage and 171 (59%) with basal
ganglia hemorrhage. A total of 159 patients (54%) showed an
additional IVH.Median age was 70 years (IQR 62–78), median
ICH volume on admission 17.7 mL (IQR 7.9–40.2), and me-
dian peak ICH volume 22.5 mL (IQR 8.9–46.4). Median PHE
volume on admission was 16.3 mL (IQR 9.1–29.2) and in-
creased to a median peak PHE volume of 37.5 mL (IQR
19.0–60.6) over a median period of 7 days (IQR 3–12). Me-
dianNIHSS on admission was 13 (IQR6–21), medianmRSon
day 90 was 4 (IQR 3 to 5). Time between symptom onset and
admission did not diﬀer between patients with and without
hematoma expansion up to day 3 (4.2 hours [IQR 2.1–9.0] and
5.0 hours [IQR 2.5–11.9], respectively, p = 0.234).
Factors influencing outcome in ICH patients
A total of 107 patients (37%) had a favorable outcome on day
90. Detailed characteristics of both outcome groups are shown
in table 1 and table e-1 (links.lww.com/WNL/A259). Besides
established prognostic factors such as ICH volume, location,
age, and IVH, frequency of elevated ICP, fever burden, neu-
trophil to lymphocytes count on day 6, and peak PHE extent
diﬀered between both outcome groups in univariate analysis.
Lymphocytes, neutrophils, and NLR on admission and day 4
did not diﬀer between the outcome groups (data not shown).
Multivariable logistic regression (table 2) revealed only peak
PHE (odds ratio[OR]/Exp[B] 0.984 for each mL of PHE) as
independent prognostic factor in ICH patients besides the
abovementioned and established measures.25 Peak PHE vol-
ume also remained the only independent outcome predictor in
our sensitivity analysis including only patients with at least 4
CT scans up to day 9 (n = 218) with a comparable OR (OR
0.985 [95% conﬁdence interval (CI) 0.973–0.997], p = 0.012)
besides and adjusted for the abovementioned factors.
Figure 1 illustrates PHE evolution in patients with favorable
and poor outcome: patients with poor outcome showed an
immense PHE increase during the ﬁrst 72 hours after ICH
onset compared to patients with a favorable outcome, and PHE
increase continued to be less pronounced up to day 10–12.
Receiver operating characteristic analysis
ROC analysis (ﬁgure e-1, links.lww.com/WNL/A258) con-
ﬁrmed a good predictive value of peak PHE regarding favor-
able outcome, especially compared to the predictive value of
initial ICH volume and the well-established ICH score.25 A
cutoﬀ value of 26.8 mL peak PHE volume was identiﬁed with
a sensitivity of 0.54 and a speciﬁcity of 0.78 (Youden Index
0.326) to distinguish best between patients with a favorable
and a poor outcome.
Measures influencing peak PHE volume
Given that peak PHE extent was identiﬁed as an independent
predictor of long-term outcome, we studied factors inﬂu-
encing peak PHE volume. As demonstrated in table 3, in
univariate analyses various measures including younger age,
location of hematoma, IVH, hematoma volume, initial PHE
increase up to day 3, fever burden, and reduced lymphocyte
count on day 4–6 as well as increased NLR on day 6 were
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associated with an increased peak PHE volume >37.495 mL
(median of the entire cohort). In multivariable testing, initial
PHE increase up to day 3 and reduced lymphocytes on day 4
remained independent predictors of an increased peak PHE
besides a younger age and a higher ICH volume (table 4).
In a propensity score–matched (PSM) subgroup analysis (n =
124) accounting for ICH volume, age, and hematoma loca-
tion, early PHE increase up to day 3 (OR 1.060 [95% CI
1.018–1.103]) and increased NLR on day 6 (OR 1.236 [95%
CI 1.034–1.477]) were associated with an increased peak
PHE (see also table e-2, links.lww.com/WNL/A259).
Measures associated with early PHE increase
up to day 3
A higher early PHE increase (PSM cohort, n = 224) was sig-
niﬁcantly associated with a higher fever burden up to day 3 (OR
1.456 [95% CI 1.103–1.920]) and a hematoma expansion >5
mL up to day 3 (OR 3.647 [95% CI 1.533–8.679]) while there
was no association with age, hematoma volume on admission,
or hematoma location, indicating a well-matched cohort. For
more detailed information, see table e-3 (links.lww.com/
WNL/A259) (only PSM data shown).
Discussion
This study suggests that peak PHE volume is an independent
predictor of day 90 outcome in ICH patients and is associated
with age, hematoma volume, initial PHE increase up to day 3,
and inﬂammatory measures. Each milliliter of additional peak
PHE volume increased the absolute risk for a poor outcome by
1.5%. In turn, initial PHE increase was related to hematoma
expansion and fever burden. These results may help to direct
further research in order to shed light into the pathophysiologic
mechanisms that act beyond perihemorrhagic edema evolution
Table 1 Clinical characteristics in favorable and poor outcome groups
Spontaneous ICH (n = 292)
Favorable outcome
(mRS 0–3; n = 107)
Poor outcome
(mRS 4–6; n = 185) p Value
Age, y, median (IQR) 69 (59–76) 72 (64–79) 0.007a
Male sex, n (%) 57 (53) 104 (56) 0.714b
NIHSS on admission, median (IQR) 5 (2–11) 16 (11–35) <0.001a
Baseline mRS, median (IQR) 1 (0–2) 1 (0–2) 0.003a
Medication on admission, n (%)
Platelet aggregation inhibitors 30 (28) 58 (31) 0.598b
VKA 16 (15) 34 (18) 0.521b
Statin 28 (26) 36 (20) 0.189b
Location lobar, n (%) 56 (52) 65 (35) 0.004b
Intraventricular hemorrhage, n (%) 38 (36) 121 (65) <0.001b
Hematoma volume on admission, mL, median (IQR) 10.6 (4.9–25.6) 21.4 (11.2–44.4) <0.001a
Hematoma expansion >5 mL, n (%) 15 (14) 46 (25) 0.028b
Perihemorrhagic edema volume on admission, mL, median (IQR) 13.7 (5.7–25.9) 18.5 (10.9–34.0) <0.001a
Perihemorrhagic edema volume increase up to day 3, mL, median (IQR) 1.97 (−0.04 to 6.5) 5.4 (−0.3 to 12.7) 0.028a
Peak perihemorrhagic edema volume, mL, median (IQR) 23.8 (9–45.3) 42.6 (28.1–67.4) <0.001a
Intracranial pressure burden up to day 12, median (IQR) 0 (0) 0 (0–5) <0.001a
Fever burden up to day 12, median (IQR) 1 (0–5) 3 (1–7) <0.001a
Lymphocytes day 6, 109/L, median (IQR) 1.4 (1.0–1.8) 1.1 (0.8–1.4) <0.001a
Neutrophil-to-lymphocyte ratio day 6, median (IQR) 4.0 (2.9–5.4) 4.61 (3.2–6.7) 0.005a
In-hospital mortality, n (%) 0 (0) 22 (12) <0.001b
mRS discharge, median (IQR) 3 (2–4) 5 (5–5) <0.001a
mRS day 90, median (IQR) 2 (2–3) 5 (4–6) <0.001a
Abbreviations: ICH = intracerebral hemorrhage; IQR = interquartile range; NIHSS =NIH Stroke Scale;mRS =modified Rankin Scale; VKA = vitamin K antagonist.
a Wilcoxon rank-sum test.
b χ2/Fisher exact test when necessary.
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and to open up avenues for potential treatment targets in
patients with ICH.
After ICH ictus, many inﬂammatory processes are initiated.1,2
Animal studies have revealed a rise of proinﬂammatory medi-
ators within hours after cerebral injury suggesting a hyper-
inﬂammatory state in the initial stages of acute brain injury26
associated with the development of brain edema.27 Rare human
data also suggested an association of edema evolution with
inﬂammatory measures (e.g., NLR,28 certain interleukins,29 or
matrix metalloproteinase-9 concentrations30). Furthermore,
the inﬂuence of immunomodulating therapies on PHE evolu-
tion also supports this association.31,32 Those inﬂammatory
processes start within hours after ICH onset and continue up to
several days.1 This underlines their importance regarding PHE
evolution both in the acute phase and in the postacute period
when PHE volume continues to increase.3 This link between
PHE evolution and inﬂammatorymeasures as well as the role of
PHE as an imaging marker of inﬂammatory processes in ICH
patients is further strengthened and conﬁrmed in light of the
ﬁndings of our study. It also supports an independent prog-
nostic eﬀect of peak PHE volume on outcome.
Previous reports found a strong correlation between PHE
volume and outcome in ICH patients when analyzing PHE
evolution up to 72 hours after onset. Wu and colleagues12
reported that the early edema extension distance increase up
to 72 hours after onset independently inﬂuenced mortality
after ICH. An analysis by Venkatasubramanian and col-
leagues33 including 27 patients found a correlation of PHE
Figure 1 Evolution of absolute hematoma and perihemorrhagic edema (PHE) volume up to day 10–12 in patients with
favorable and poor outcome
Only patientswith ≥5 CT scans up to day 10–12
(n = 170) were included. Blue lines represent
favorable outcomes, red lines poor outcomes,
dotted lines hematoma volumes, and contin-
uous lines perihemorrhagic edema (PHE) vol-
umes. Patientswith poor outcome showednot
only a higher PHE volume increase during the
first 72 hours after onset compared to patients
with favorable outcome, but also to a lesser
extent up to day 10–12.
Table 2 Multivariable logistic regression model modeling the prediction of favorable outcome (modified Rankin Scale
0–3) in the intracerebral hemorrhage cohort (n = 292)
Odds ratio, Exp(B) 95% CI p Value
Intraventricular hemorrhage 0.486 0.256–0.887 0.019
NIHSS on admission 0.936 0.906–0.968 <0.001
Age, y 0.944 0.918–0.972 <0.001
Hematoma volume by location, mL 0.967 0.944–0.990 0.006
Peak perihemorrhagic edema volume, mL 0.984 0.973–0.994 0.002
Abbreviations: CI = confidence interval; NIHSS = NIH Stroke Scale.
Hematoma volume by location represents the interaction term hematoma volume × location with location (basal ganglia vs lobar)–dependent effects of
hematoma volume.
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volume growth up to 48 hours with clinical status at 48 hours
while there was no association of total PHE volume growth
with 3-month functional outcome. A pooled analysis of the
INTERACT data showed that early PHE increase up to 24
hours after onset is an independent predictor of death and
dependency on day 90 after ICH.9 Similar results could also
be shown by Urday et al.11 and Murthy et al.,34 leading to
consistent results observed in about 3,000 patients. Our data
revealed an unadjusted association of early PHE increase with
outcome. Furthermore, as we included PHE data of a wide
temporal range, our data suggest that it is primarily the peak
PHE volume that matters regarding outcome measures. On
the other hand, our analysis also demonstrated an in-
dependent correlation of early PHE increase with peak PHE
volume. Thus, early PHE increase may serve as a predictor of
peak PHE volume. The latter was independently associated
with poor outcome in our cohort.
Several therapeutic options targeting the abovementioned
mechanisms may evolve. At ﬁrst sight, removing the blood
clot might be the most pragmatic approach. However, so far
a general superiority of surgical intervention in ICH patients
as compared to conservative treatment could not be shown.35
A minimally invasive approach is currently tested in the
MISTIE trial, so far yielding promising results concerning
PHE reduction in the phase II trial,36 however, with an in-
creased rate of asymptomatic bleeding in patients treated with
minimally invasive surgery plus alteplase for clot removal.7
Hematoma expansion could be limited by administration
of a hemostatic therapy with rFVIIa, however, with no
Table 4 Multivariable logistic regression model modeling the prediction of a perihemorrhagic edema (PHE) volume
>37.495 mL (median PHE volume of the entire intracerebral hemorrhage cohort [n = 292])
Odds ratio, Exp(B) 95% CI p Value
Initial PHE volume increase up to day 3, mL 1.067 1.032–1.104 <0.001
Hematoma volume on admission, mL 1.087 1.063–1.112 <0.001
Hematoma expansion >5 mL 5.749 2.304–14.341 <0.001
Age, y 0.970 0.947–0.995 0.017
Lymphocytes on day 4, 109/L 0.394 0.204–0.761 0.006
Abbreviation: CI = confidence interval.
Table 3 Characteristics of patients with larger and smaller peak perihemorrhagic edema (PHE) volume dichotomized
according to median peak PHE volume of the entire cohort (37.495 mL)
Spontaneous ICH (n = 292)
Peak PHE volume ≤37.495 mL
(n = 146)
Peak PHE volume >37.495 mL
(n = 146) p Value
Age, y, median (IQR) 71 (64–80) 69 (61–77) 0.046a
Male sex, n (%) 73 (50) 88 (60) 0.099b
Location lobar, n (%) 94 (64) 77 (53) 0.043b
Intraventricular hemorrhage, n (%) 71 (49) 88 (60) 0.046b
Hematoma volume on admission, mL, median (IQR) 8.7 (4.2–17.9) 35.0 (17.5–53.8) <0.001a
Hematoma expansion >5 mL, n (%) 9 (6) 52 (36) <0.001b
PHE volume on admission, mL, median (IQR) 10.4 (5.6–15.1) 28.1 (18.4–45.6) <0.001a
PHE volume increase up to day 3, mL, median (IQR) 2.1 (−0.1 to 5.3) 8.6 (−0.6 to 17.2) <0.001a
Fever burden up to day 12, median (IQR) 14 (10–18) 19 (12–26) <0.001a
Lymphocytes day 4, 109/L, median (IQR) 1.3 (1.0–1.7) 1.1 (0.8–1.5) 0.008a
Lymphocytes day 6, 109/L, median (IQR) 1.3 (0.9–1.6) 1.1 (0.8–1.4) 0.006a
Neutrophil to lymphocyte ratio day 6, median (IQR) 4.2 (3.1–5.6) 4.6 (3.2–6.9) 0.031a
Abbreviations: ICH = intracerebral hemorrhage; IQR = interquartile range.
a Wilcoxon rank-sum test.
b χ2/Fisher exact test when necessary.
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improvement in survival or functional outcome. PHE evolu-
tion was not analyzed in this trial.8 Another approach tar-
geting multiple pathophysiologic pathways associated with
PHE evolution is therapeutic hypothermia.26 Therapeutic
hypothermia eﬀectively reduced PHE volume,32 especially
when initiated early after ICH onset.37 These ﬁndings un-
derline the importance of early inﬂammatory processes re-
garding PHE evolution, as suggested in our study. However,
the question how long to treat and which target temperature
to obtain to improve outcome needs to be elucidated in future
research. A third possible treatment target is inﬂammation.
Only a few studies with small patient numbers analyzed the
eﬀect of corticosteroids in ICH patients and found no eﬀect
on mortality and infections.38 Thus, European Stroke Orga-
nisation guidelines do not recommend the use of cortico-
steroids at this time.39 Other anti-inﬂammatory substances, e.
g., ﬁngolimod, are under clinical investigation.31 However, it
remains to be elucidated whether the inﬂammatory response
related to PHE evolution represents rather a reaction to the
occurrence of blood within brain parenchyma, a reaction to
additional infectious diseases in severely ill patients, or both,
and whether an immunosuppressive strategy, an anti-
infectious strategy, or both will resolve the inﬂammatory di-
lemma in ICH patients.
There are several strengths of the present study: we could
include a sound cohort of an adequate size with available long-
term data regarding PHE evolution and outcome assessment.
Furthermore, a validated measurement was used for quanti-
ﬁcation of PHE and ICH volume,17 yielding reliable and ro-
bust results.
There are also several limitations. Despite the proper size of
the included cohort, only patients from a single center were
included. Due to the retrospective design, there were no
standardized time points of imaging. To obtain comparable
results, we merged imaging data within prespeciﬁed time
clusters. This procedure might lead to an underestimation
of peak PHE volume and also to a distorted representation of
early PHE volume increase up to day 3 and the time axis of
PHE evolution. However, this bias exists for all outcome
groups. Due to the exclusive inclusion of supratentorial ICH
patients, no statement about the association of PHE with
functional outcome in infratentorial ICH patients is yet pos-
sible. A further selection bias also cannot be excluded as we
did not include patients with early withdrawal of care and
patients with only 1 CT scan (n = 294) and excluded 38
patients due to missing data. Because length of hospital stay
and number of CT scans varied between individuals, in some
patients the real peak PHE volume might not have been
assessed. We used the method of median split to assess
measures inﬂuencing peak PHE volume leading to a possible
loss of power in this analysis. Validation of our methodology
was performed up to day 5 after admission. We cannot ex-
clude that due to ongoing hematoma degradation a certain
inaccuracy may aﬀect our PHE assessment between day 6 and
12, even if our method corrects for hematoma degradation.
Time between symptom onset and admission did not diﬀer
between patients with and without hematoma expansion.
However, as this measure diﬀered between individual
patients, it might pose possible bias in this complex relation
among hematoma evolution, PHE evolution, outcome, and
time.
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Study question
Are peak perihemorrhagic edema (PHE) volumes associated
with functional outcomes 90 days after intracerebral hemor-
rhage (ICH)?
Summary answer
Greater PHE volumes are associated with worse 90-day post-
ICH functional outcomes.
What is known and what this paper adds
PHE volumes peak within approximately 8–12 days of the
ictus, and this growth is thought to induce clinical de-
terioration. This study provides evidence that peak PHE
volumes are in fact predictors of long-term post-ICH func-
tional outcomes.
Participants and setting
This study examined 292 patients (55% male) with sponta-
neous supratentorial ICH who were admitted to the Neuro-
logical Department of the University of Erlangen-Nuremberg
between January 2006 and January 2014. All had a baseline
modiﬁed Rankin Scale (mRS) score of <4.
Design, size, and duration
The study reviewed CT scans in patient medical records to
determine peak PHE volumes observed mainly within 12 days
of admission. Patient functionality was assessed based on
mRS scores.
Primary outcomes
The primary outcome was the 90-day post-ICH mRS score,
which was determined via mailed questionnaires or telephone
interviews with patients or their next of kin. Scores of 0–3
were classiﬁed as favorable outcomes, and scores of 4–6 were
classiﬁed as poor outcomes.
Main results and the role of chance
Favorable 90-day outcomes were recorded for 107 (37%)
patients, whereas unfavorable outcomes were recorded for 185
(63%) patients. The peak PHE volumes were smaller for
patients with favorable outcomes than for patients with un-
favorable outcomes (medians [interquartile ranges], 23.8
[9–45.3] mL vs 42.6 [28.1–67.4] mL; p < 0.001). Multivariable
logistic regression conﬁrmed that greater peak PHE volumes
reduced the chances of a favorable outcome (odds ratio, 0.984
per mL; 95% CI, 0.973–0.994; p = 0.002). A receiver operating
characteristics analysis showed that a 26.8-mL cut-oﬀ value for
the peak PHE volume predicted a poor outcome with 54%
sensitivity and 78% speciﬁcity.
Bias, confounding, and other reasons for
caution
This study examined patients at only one center. Furthermore,
the imaging timepoints were not standardized, and the exclusion
of patients with insuﬃcient CT scans for determination of peak
PHE volumes might have introduced selection bias.
Generalizability to other populations
This study exclusively examined patients with supratentorial
ICH, so the results may not be generalizable to patients with
infratentorial ICH.
Study funding/potential competing interests
This study received no funding, and the authors report
no competing interests. Go to Neurology.org/N for full
disclosures.
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